These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 37022618)

  • 1. Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: The more, the better?
    Haist M; Stege H; Kuske M; Bauer J; Klumpp A; Grabbe S; Bros M
    Cancer Metastasis Rev; 2023 Jun; 42(2):481-505. PubMed ID: 37022618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
    Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
    Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma.
    Lelliott EJ; McArthur GA; Oliaro J; Sheppard KE
    Front Immunol; 2021; 12():661737. PubMed ID: 34025662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma: A Review.
    Dummer R; Ascierto PA; Nathan P; Robert C; Schadendorf D
    JAMA Oncol; 2020 Dec; 6(12):1957-1966. PubMed ID: 32970096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF inhibitors and their immunological effects in malignant melanoma.
    Adams R; Coumbe JEM; Coumbe BGT; Thomas J; Willsmore Z; Dimitrievska M; Yasuzawa-Parker M; Hoyle M; Ingar S; Geh JLC; MacKenzie Ross AD; Healy C; Papa S; Lacy KE; Karagiannis SN
    Expert Rev Clin Immunol; 2022 Apr; 18(4):347-362. PubMed ID: 35195495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
    Kelley MC
    Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy.
    Kuske M; Westphal D; Wehner R; Schmitz M; Beissert S; Praetorius C; Meier F
    Pharmacol Res; 2018 Oct; 136():151-159. PubMed ID: 30145328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma proteome alterations by MAPK inhibitors in BRAF
    Babačić H; Eriksson H; Pernemalm M
    Neoplasia; 2021 Aug; 23(8):783-791. PubMed ID: 34246984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure?
    Schummer P; Schilling B; Gesierich A
    Am J Clin Dermatol; 2020 Aug; 21(4):493-504. PubMed ID: 32124332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined BRAF-Targeted Therapy with Immunotherapy in BRAF-Mutated Advanced Melanoma Patients.
    Ferrucci PF; Lens M; Cocorocchio E
    Curr Oncol Rep; 2021 Nov; 23(12):138. PubMed ID: 34735635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frontline BRAF Testing-Guided Treatment for Advanced Melanoma in the Era of Immunotherapies: A Cost-Utility Analysis Based on Long-term Survival Data.
    Wu B; Shi L
    JAMA Dermatol; 2020 Nov; 156(11):1177-1184. PubMed ID: 32697281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melanoma with genetic alterations beyond the BRAFV600 mutation: management and new insights.
    Awada G; Neyns B
    Curr Opin Oncol; 2022 Mar; 34(2):115-122. PubMed ID: 35050937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triplet Therapy in Melanoma - Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies.
    Dixon-Douglas JR; Patel RP; Somasundram PM; McArthur GA
    Curr Oncol Rep; 2022 Aug; 24(8):1071-1079. PubMed ID: 35366166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma.
    Dimitriou F; Urner-Bloch U; Eggenschwiler C; Mitsakakis N; Mangana J; Dummer R; Urner M
    Eur J Cancer; 2021 Feb; 144():215-223. PubMed ID: 33373866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy.
    Samlowski W; Adajar C
    BMC Cancer; 2021 Nov; 21(1):1187. PubMed ID: 34743688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of Resistance to BRAF-Targeted Melanoma Therapies.
    Dulgar O; Kutuk T; Eroglu Z
    Am J Clin Dermatol; 2021 Jan; 22(1):1-10. PubMed ID: 33368052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
    Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
    Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combinatorial Approaches to the Treatment of Advanced Melanoma.
    Munhoz RR; Postow MA
    Hematol Oncol Clin North Am; 2021 Feb; 35(1):145-158. PubMed ID: 33759771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal strategy in managing advanced melanoma.
    Uchi H
    J Dermatol; 2024 Mar; 51(3):324-334. PubMed ID: 38087810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.